Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:56:41 EDT Mon 06 Oct 2025
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.11.41·1.450.21.4465+0.06154.4148.51912201.40  1.4598  1.391.9195  0.942512:37:17Sep 3015 min RT 2¢

Recent Trades - Last 10 of 220
Time ETExPriceChangeVolume
12:37:17Z1.44060.060628
12:36:35Z1.44990.069930
12:36:03Z1.44650.06151,000
12:35:59Z1.4410.056975
12:35:59Z1.44010.060161
12:35:39Z1.4450.06500
12:33:25Z1.4450.06100
12:33:01Z1.44870.0637200
12:32:35Z1.4450.0655
12:30:22Z1.450.0710

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-09-30 08:45U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Annual Report
2025-09-11 08:30U:NNVCNews ReleaseRETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
2025-09-09 08:51U:NNVCNews ReleaseNanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
2025-08-18 08:30U:NNVCNews ReleaseA Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
2025-07-30 08:30U:NNVCNews ReleaseMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
2025-07-23 08:30U:NNVCNews ReleaseNanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
2025-07-21 06:30U:NNVCNews ReleaseMeasles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
2025-07-16 08:30U:NNVCNews ReleaseWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
2025-07-14 06:30U:NNVCNews ReleaseAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
2025-07-01 06:41U:NNVCNews ReleaseThere is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
2025-06-18 06:30U:NNVCNews ReleaseWith Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
2025-06-04 06:55U:NNVCNews ReleaseNanoViricides Measles Drug Development Animal Study is Imminent
2025-05-28 06:31U:NNVCNews ReleaseNanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
2025-05-22 06:31U:NNVCNews ReleaseThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
2025-05-16 06:31U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
2025-05-14 06:31U:NNVCNews ReleaseMeasles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
2025-05-08 06:31U:NNVCNews ReleaseBroad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
2025-05-05 06:31U:NNVCNews ReleaseNanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
2025-04-29 06:31U:NNVCNews ReleaseMeasles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
2025-04-14 06:32U:NNVCNews ReleaseMeasles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak